2Rezkalia S H, Kloner R A.No-reflow phenomenon [J].Cireulation, 2002( 105 ) : 656-662.
3Lincoff A M, Califf R M, Vande Wed F, et al.Mortality at 1 year with combination platelet glycoprotein IIb,rIIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibri- nolytic therapy for acute myocardial infarctioon:GUSTO V Randomized Trial [ J ].JAMA, 2002,288 ( 17 ) : 2130-2135.
4Petronio A S, Rovai D, Musumeci G, et al.Effects of abcix- imab on microvascular integrity and left ventricular function- al vecovery in patients with acute infarction treated by pri- mary coronary angioplasty[J].Eur Heart J,2003, 24:67-76.
6Kawano H,Hayashida T,Ohtani H,et al.Histopathological findings of the no-reflow phenomenon following coronary in- tervention for acutecoronary syndrome [J].Int Heart J,2005, 46(2) :327-332.
7Harem C W,Heeshen C,Goldman B,et al.For the Capture Investigators.Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels [J ].N Eng! J Med, 1999,340:1623-1629.
8Morishima I, SoneT, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with pereutaneous transluminal coronary angioplasty for first acute myocardial infarction [J].Am Coil Cardiol, 2000,36(4) : 1202.
9Christiansen J P, Leong-Poi H, Klibanov A L, et al.Noninva- sive imaging of myocardial reperfusion injury using leuko- cyte-targeted contrast echocardiography [J].Circulation, 2002,105:1764-1767.
